Posts by: Alberto Molano, PhD

Alberto Molano, PhD

Alberto Molano was born in Bogotá, Colombia. He studied medicine at Universidad del Rosario and obtained a Ph.D. in Immunology from Weill Cornell Graduate School of Medical Sciences in New York. He conducted research and authored or co-authored twenty publications on molecular and cellular immunology, autoimmunity, immunology of aging and parasite immunology.

July 8, 2019August 9, 2019

Miscarriage or Ectopic Pregnancy Not More Likely in Women Using Rebif, Study Suggests

News

Results from a large observational study of pregnant women with multiple sclerosis (MS) treated with an interferon (IFN) beta-1a, like Rebif, before and during the first trimester showed no elevated ... Read more

June 17, 2019June 18, 2019

Relative Cancer Risk is Higher in MS Patients Who Switch Disease-modifying Treatments More Frequently, Study Finds

News

The relative risk of developing cancer was found to be higher in multiple sclerosis patients who more frequently switched between disease-modifying treatments, according to a study. In addition, researchers found ... Read more

May 23, 2019May 23, 2019

Early Safety Data from Phase 1 Study of Immunotherapy in Progressive MS Patients To Be Detailed at EAN

News

Early, positive safety results from a Phase 1 trial testing a potential immunotherapy, ATA188, in people with progressive multiple sclerosis will be detailed at the 5th Congress of the European Academy ... Read more

April 29, 2019May 8, 2019

Machine System Based on Brain Activity May Restore Speech to Those Who Lost It, Study Reports

News

A study suggests that it may be possible to create synthetic speech based on recordings of brain activity in people with irreversible speech loss due to neurological ills, such ... Read more

April 8, 2019

In-Depth Study into MS Progression Gets $2M Boost from Roche Canada

News

Roche Canada is contributing $2.125 million to the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo), a partnership initiative with the Multiple Sclerosis Society of Canada, the ... Read more

March 29, 2019March 29, 2019

$1.5M Earmarked for MS Research on Cannabis in Canada

News

In partnership with the Canadian Institutes of Health Research, the MS Society of Canada has announced $1.5 million to fund research over five years on the effects of cannabis on multiple sclerosis ... Read more

March 11, 2019March 11, 2019

Immunic Therapeutics Enrolls First Patient in Phase 2 Trial of IMU-838 for RRMS

Aubagio, News

Immunic Therapeutics has enrolled the first patient in its Phase 2 clinical trial testing IMU-838, a potential oral therapy for relapsing-remitting multiple sclerosis (RRMS). IMU-838 (vidofludimus calcium) is a next-generation selective ... Read more

February 25, 2019February 28, 2019

Study Indicates Possible Correlation Between Nutritional Status, MS

News

Multiple sclerosis (MS) patients eat a more limited diet, with a lower average of 31 nutrients, including zinc, thiamin, and iron, when compared with healthy controls, a study shows. ... Read more

January 22, 2019January 22, 2019

Controlling Spasticity Would Greatly Improve Everyday Quality of Life, Survey Shows

News

An international survey of caregivers and adults with neurological diseases, including multiple sclerosis (MS), revealed that spasticity is a hidden burden, having a negative effect on the ability to ... Read more

January 4, 2019January 10, 2019

Bafiertam, a Bioequivalent of Tecfidera, Receives Tentative OK from FDA for RRMS

News

Banner Life Sciences has received tentative approval from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for Bafiertam (monomethyl fumarate), a novel bioequivalent of Biogen’s ... Read more

December 21, 2018January 3, 2019

Study Links Food Allergies and Increased MS Disease Activity

News

Multiple sclerosis (MS) patients who reported food allergies showed a 27 percent higher cumulative rate of flare-ups over the course of their disease, and more than twice the likelihood ... Read more

December 19, 2018December 19, 2018

FDA Gives Green Light to Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Patients

News

The U.S. Food and Drug Administration (FDA) has approved BrainStorm Cell Therapeutics‘ request to open a Phase 2 clinical trial testing the safety and effectiveness of its proprietary NurOwn mesenchymal ... Read more

December 7, 2018December 7, 2018

Tysabri Seen as Superior to IFN-β in Preventing Relapses, Easing Disability in Small Study

News

Tysabri (natalizumab) was found to be superior to interferon beta (IFN-β) in a small, 12-month study with relapsing-remitting multiple sclerosis (RRMS) patients, significantly decreasing their disability levels, its researchers ... Read more

November 30, 2018December 5, 2018

CDC Launching National Neurological Conditions Surveillance System to Study MS

News

The U.S. Congress is supporting with $5 million the National Neurological Conditions Surveillance System (NNCSS), an initiative to be launched by the Centers for Disease Control and Prevention (CDC) ... Read more

November 13, 2018November 13, 2018

Heavy Caseloads for MS Specialist Nurses in UK Compromise Patient Care, MS Trust Reports

News

Nurses who specialize in treating multiple sclerosis (MS) patients in the U.K. are handling heavier caseloads than recommended or preferred, resulting in patients going without the necessary care and support ... Read more

November 9, 2018November 9, 2018

Study Highlights Need for Better Engagement Between MS Patients and Healthcare Providers

News

Multiple sclerosis (MS) relapses can be challenging for some patients, and better engagement is needed between patients and their healthcare providers, a study focused on patient experiences has found. ... Read more

Pin It on Pinterest